Forchheim, Germany Clinical Trials

A listing of Forchheim, Germany clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 44 clinical trials
A Study of PRN1008 in Patients With Pemphigus

This is a Phase 3 randomized, parallel-group, double-blind, placebo-controlled trial (Blinded Treatment Period) followed by an Open-Label Extension Period intended to evaluate the efficacy and safety of oral PRN1008 in moderate to severe pemphigus. After completing the Open-Label Extension Period, eligible patients may continue in a Long Term Extension Period …

autoantibody titer
pemphigus foliaceus
renal function
Central Recruiting (Principia Biopharma)
 (8.7 away) Contact site
  • 158 views
  • 26 Aug, 2020
  • +158 other locations
Comparison Between Two Dose Levels of Daunorubicin and Between One vs. Two Induction Cycles for Adult Patients With AML

The proposed trial will address two clinically important questions for younger patients with newly diagnosed acute myeloid leukemia (AML): the optimal dose of daunorubicin in induction therapy and the necessity of a second induction cycle in patients with a good response after the first induction. The primary endpoint is the …

daunorubicin
ejection fraction
neoadjuvant therapy
acute promyelocytic leukemia
minimal residual disease
Universit tsklinikum Erlangen
 (9.4 away) Contact site
  • 33 views
  • 12 Aug, 2020
  • +40 other locations
A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Biologic Therapy

The objective of this study is to evaluate the efficacy and safety of upadacitinib compared to placebo as induction therapy in participants with moderately and severely active Crohn's disease (CD).

vedolizumab
ustekinumab
certolizumab pegol
adalimumab
crohn's disease
Universitaetsklinikum Erlangen /ID# 203551
 (8.7 away) Contact site
  • 596 views
  • 24 Nov, 2020
  • +685 other locations
Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS)

The purpose of this study is to demonstrate superiority of secukinumab at Week 16, based on Hidradenitis Suppurativa Clinical Response (HiSCR) rates versus placebo, along with the maintenance of efficacy of secukinumab at Week 52 in subjects with moderate to severe HS. Moreover, this study will also assess the safety …

antiseptics
secukinumab
abscess
hidradenitis
Novartis Investigative Site
 (8.7 away) Contact site
  • 909 views
  • 08 Oct, 2020
  • +111 other locations
Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866)

A global study to evaluate peri-operative pembrolizumab with chemotherapy versus placebo to pembrolizumab plus chemotherapy in cisplatin eligible patients.

Universitaetsklinikum Erlangen ( Site 0505)
 (8.7 away) Contact site
  • 58 views
  • 25 Nov, 2020
  • +179 other locations
A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease

The researchers are doing this study to see if semaglutide can slow down the growth and worsening of chronic kidney disease in people with type 2 diabetes. Participants will get semaglutide (active medicine) or placebo ('dummy medicine'). This is known as participants' study medicine - which treatment participants get is …

angiotensin converting enzyme
renal impairment
semaglutide
chronic disease
Novo Nordisk Investigational Site
 (8.7 away) Contact site
  • 960 views
  • 25 Nov, 2020
  • +518 other locations
A Study of the Efficacy and Safety of Upadacitnib (ABT-494) in Participants With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Conventional and/or Biologic Therapies

The objective of this study is to evaluate the efficacy and safety of upadacitinib compared to placebo as induction therapy in participants with moderately and severely active Crohn's disease (CD).

immunosuppressive agents
endoscopy
corticosteroids
abdominal pain
mucosal inflammation
Universitaetsklinikum Erlangen /ID# 203552
 (8.7 away) Contact site
  • 824 views
  • 25 Nov, 2020
  • +664 other locations
An Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Genital Psoriasis

This Phase 3 multicenter, randomized, placebo-controlled, double-blind study is designed to evaluate the efficacy and safety of apremilast in subjects with moderate to severe genital psoriasis (modified sPGA-G 3, moderate or severe). Approximately 332 subjects with moderate to severe genital psoriasis will be randomized 1:1 to receive either apremilast 30 …

plaque psoriasis
apremilast
cc-10004
Hautklinik Universitatsklinikum Erlangen
 (8.7 away) Contact site
  • 210 views
  • 28 Oct, 2020
  • +119 other locations
A Study to Test the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis

This is a study to demonstrate the clinical efficacy, safety and tolerability of bimekizumab administered subcutaneously (sc) compared with placebo in the treatment of subjects with active Psoriatic Arthritis (PsA).

bimekizumab
methotrexate
hydroxychloroquine
joints tender
rheumatoid factor
Pa0010 40023
 (9.4 away) Contact site
  • 235 views
  • 19 Nov, 2020
  • +306 other locations
Efficacy and Safety Study of Apremilast (CC-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque Psoriasis

This is a Phase 3, multicenter, randomized, placebo-controlled, double-blind study of the efficacy and safety of apremilast (CC-10004) in pediatric subjects with moderate to severe plaque psoriasis. At least 230 pediatric subjects (ages 6 through 17 years) will be randomized 2:1 to receive either apremilast or placebo for the first …

cc-10004
plaque psoriasis
phototherapy
systemic therapy
apremilast
Universitatsklinikum Erlangen
 (9.5 away) Contact site
  • 98 views
  • 27 Aug, 2020
  • +191 other locations